-----begin privacy-enhanced message----- proc-type: 2001,mic-clear originator-name: webmaster@www.sec.gov originator-key-asymmetric: mfgwcgyevqgbaqicaf8dsgawrwjaw2snkk9avtbzyzmr6agjlwyk3xmzv3dtinen twsm7vrzladbmyqaionwg5sdw3p6oam5d3tdezxmm7z1t+b+twidaqab mic-info: rsa-md5,rsa, fkhb36eyaa+gda9v4ww3/4mmvgbiax5duz0jbjvjxlptlsf3+zsp7aaplxx3osk3 /tt+fobudeia5fjcq5xaba== 0001183740-07-000190.txt : 20070411 0001183740-07-000190.hdr.sgml : 20070411 20070411165044 accession number:		0001183740-07-000190 conformed submission type:	sc 13d public document count:		1 filed as of date:		20070411 date as of change:		20070411 subject company:	 	company data:	 		company conformed name:			cellcyte genetics corp 		central index key:			0001325279 		standard industrial classification:	metal mining [1000] 		irs number:				000000000 		state of incorporation:			nv 		fiscal year end:			1231 	filing values: 		form type:		sc 13d 		sec act:		1934 act 		sec file number:	005-82283 		film number:		07761657 	business address:	 		street 1:		470 granville street 		street 2:		suite 318 		city:			vancouver 		state:			a1 		zip:			v6c 1v5 		business phone:		604-719-8129 	mail address:	 		street 1:		470 granville street 		street 2:		suite 318 		city:			vancouver 		state:			a1 		zip:			v6c 1v5 	former company:	 		former conformed name:	shepard inc. 		date of name change:	20050428 filed by:		 	company data:	 		company conformed name:			reys gary a 		central index key:			0001394891 	filing values: 		form type:		sc 13d 	business address:	 		business phone:		206-910-9244 	mail address:	 		street 1:		1815 east lancaster rd 		city:			freeland 		state:			wa 		zip:			98249 sc 13d 1 s13d-r.htm s13d-r united states securities and exchange commission washington, d.c. 20549 schedule 13d under the securities exchange act of 1934 (amendment no. ___)* cellcyte genetics corporation ________________________________________________________________________________ (name of issuer) common stock -- par value $0.001 per share ________________________________________________________________________________ (title of class of securities) 15116p 10 3 ______________________________________ (cusip number) gary a. reys c/o cellcyte genetics corporation 5400 carillon point, kirkland, washington, u.s.a., 98033 telephone: (425) 576-4106 ________________________________________________________________________________ (name, address and telephone number of person authorized to receive notices and communications) march 30, 2007 ________________________________________________________________________________ (date of event which requires filing of this statement) if the filing person has previously filed a statement on schedule 13g to report the acquisition that is the subject of this schedule 13d, and is filing this schedule because of section section 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. &#163; *the remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. the information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of section 18 of the securities exchange act of 1934 ("act") or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act (however, see the notes). cusip no. 15116p 10 3 1. names of reporting persons gary a. reys. i.r.s. identification nos. of above persons (entities only). 2. check the appropriate box if a member of a group ( see instructions) (a) &#163; (b) &#163; not applicable. 3. sec use only: 4. source of funds (see instruction): oo, pf. 5. check if disclosure of legal proceedings is required pursuant to items 2(d) or 2(e): &#163; not applicable. 6. citizenship or place of organization: united states. number of shares beneficially by owned by each reporting person with: 7. sole voting power: 18,625,000 shares (1) . 8. shared voting power: nil. 9. sole dispositive power: 18,625,000 shares (1) . 10. shared dispositive power: nil. 11. aggregate amount beneficially owned by each reporting person: 18,625,000 shares (1) . 12. check if the aggregate amount in row (11) excludes certain shares ( see instructions ): not applicable. 13. percent of class represented by amount in row (11): 31.2% (1)(2) . 14. type of reporting person ( see instructions): in. notes: (1) the filing of this statement by the reporting person shall not be construed as an admission that the reporting person is, for the purposes of section 13(d) or 13(g) of the act, the beneficial owner of any securities covered by the statements herein. (2) based on 59,649,225 shares of the issuer's common stock issued and outstanding as of march 30, 2007. page 2 of 6 cusip no. 15116p 10 3 this statement on schedule 13d is filed pursuant to rule 13d-1(d) under the securities exchange act of 1934 , as amended. gary a. reys is sometimes referred to herein as the "reporting person." item 1. security and issuer this statement relates to the voting common stock, $0.001 par value, of cellcyte genetics corporation, a nevada corporation (the "issuer"). the issuer maintains its principal executive offices at 5400 carillon point, kirkland, washington, u.s.a., 98033 item 2. identity and background name: this statement is filed by gary a. reys. residence or business address: c/o cellcyte genetics corporation 5400 carillon point, kirkland, washington, u.s.a., 98033 present principal occupation or employment: the reporting person's present principal occupation is as a businessman. he became the chairman, president, chief executive officer, principal executive officer and a director of the issuer on march 30, 2007. criminal proceedings: during the last five years, the reporting person has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors). civil proceedings: during the last five years, the reporting person has not been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction where, as a result of such proceeding, there was or is a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. citizenship: the reporting person is a citizen of the united states. item 3. source and amount of funds or other consideration on march 30, 2007, the issuer completed the acquisition (the "acquisition") of all of the issued and outstanding shares of cellcyte genetics corporation, a private washington corporation ("cellcyte-washington") pursuant to a share exchange agreement among cellcyte-washington, the shareholders of cellcyte-washington (including the reporting person) and the issuer, dated as fully executed on march 14, 2007. at the closing of the acquisition: page 3 of 6 cusip no. 15116p 10 3 the issuer issued 8,000,000 shares of common stock at a deemed issuance price of $1.50 per share ($12,000,000 total) to the reporting person in consideration for his interest in cellcyte-washington; 9,375,000 restricted shares of the issuer's common stock held by one of the issuer's directors were transferred to the reporting person at a deemed transfer price of $0.0001 per share ($937.50 total from the reporting person's personal funds); and 1,250,000 shares of the issuer's common stock held by certain other shareholders of the issuer were transferred to the reporting person at a deemed transfer price of $0.0001 per share ($125.00 total from the reporting person's personal funds). item 4. purpose of transaction the reporting person's acquisition of the issuer's shares as described above in item 3 was in relation to the issuer's acquisition of cellcyte-washington, of which the reporting person was a co-founder and major shareholder. as a result of such transaction, the reporting person became a major shareholder and an officer and director of the issuer. subject to all relevant securities law restrictions, the reporting person may acquire or dispose of securities of the issuer from time to time in the open market or in privately negotiated transactions with third parties, subject to and depending upon prevailing market conditions for such securities. except as otherwise disclosed herein, reporting person has no current plans or proposals that relate to or would result in: the acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer; any extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer or any of its subsidiaries; a sale or transfer of a material amount of the assets of the issuer or any of its subsidiaries; any change in the present board of directors or management of the issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; any material change in the present capitalization or dividend policy of the issuer; any other material change in the issuer's business or corporate structure including, but not limited to, if the issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the investment company act of 1940; changes in the issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede acquisition of control of the issuer by any person; causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; a class of equity securities of the issuer becoming eligible for termination of registration pursuant to section 12(g)(4) of the act; or any action similar to any of those enumerated above. page 4 of 6 cusip no. 15116p 10 3 item 5. interest in securities of the issuer the filing of this statement by the reporting person shall not be construed as an admission that the reporting person is, for the purposes of section 13(d) or 13(g) of the act, the beneficial owner of any securities covered by the statements herein. for the purposes of this statement, the reporting person is reporting herein that as of march 30, 2007, the reporting person was the beneficial owner of 18,625,000 (or approximately 31.2%) of the issuer's common stock. for the purposes of this statement, the reporting person is reporting herein that as of march 30, 2007, the reporting person had the sole power to vote or to direct the voting of, or to dispose or to direct the disposition of, 18,625,000 (or approximately 31.2%) of the issuer's common stock. as of march 30, 2007, and within the sixty day period prior thereto, no transactions involving the issuer's equity securities had been engaged in by the reporting person other than as disclosed herein. as of march 30, 2007, to the best knowledge and belief of the undersigned, no person other than the reporting person had the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the issuer's equity securities. not applicable. item 6. contracts, arrangements, understandings or relationships with respect to securities of the issuer except as disclosed herein, the reporting person does not have any contract, arrangement, understanding or relationship with respect to securities of the issuer including, but not limited to, transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies, and the reporting person has not pledged securities of the issuer nor are the securities of the issuer held by the reporting person subject to a contingency, the occurrence of which would give another person voting power or investment power over such securities. item 7. material to be filed as exhibits not applicable. page 5 of 6 cusip no. 15116p 10 3 signature after reasonable inquiry and to the best of the knowledge and belief of the undersigned, the undersigned certifies that the information set forth in this statement is true, complete and correct. dated: april 9, 2007. /s/ gary a. reys __________________________ gary a. reys page 6 of 6 -----end privacy-enhanced message----- 